Tianyin Pharmaceutical Signs Over 60 New Distribution Agreements with 15 Regional...

Tianyin Pharmaceutical Signs Over 60 New Distribution Agreements with 15
Regional Distributors

CHENGDU, China, May 20 /Xinhua-PRNewswire-FirstCall/ -- Tianyin
Pharmaceutical, Co., Inc., (OTC Bulletin Board: TYNP), a manufacturer and
supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu,
China, today announced that it signed over 60 new distribution agreements with
a total of 15 regional distributors, including both new and previously
contracted distributors.
Many of these agreements, which are for a term of one year, were signed
with several of the Company's top 10 distributors from 2007. Newly engaged
distributors include Sichuan Kelun Medicine & Trade Co., Ltd. and Zhejiang
Huadong Medicine Co., Ltd. Based upon the results of previous years'
agreements, and expected results from the new agreements, management believes
that all of the 2008 distribution agreements have the potential to generate
over an aggregate of $10 million in product orders, which would represent a
20% increase over the results received from last year's distribution
agreements.
The distribution agreements cover 27 existing products from last year's
agreements and 1 newly launched drug, the Azithromycin Dispersible Tablet,
which is used for Upper and lower respiratory tract infections and other
bacterial infections in the skin and reproductive system. The Company's two
flagship products, Arpu Shuangxin Oral Liquid and Ginkgo Mihuan Oral Liquid,
along with any other new drugs that we launch during 2008 are not included in
the distribution agreements discussed herein.
"This accomplishment is significant for several reasons and demonstrates
Tianyin Pharmaceutical's ability to expand its geographic footprint and
distribution channels for both existing and new products. This will help us to
gain incremental market share, which will ultimately drive future revenue
growth. We recently initiated production to fulfill orders for the 28 products
referenced above and anticipate initial contribution from these agreements
during the fourth quarter of fiscal year 2008, which ends June 30, 2008. We
are committed to working closely with our long term distribution partners as
well as newly engaged distribution partners and expect to secure additional
orders from these relationships in the coming months," commented Dr. Guoqing
Jiang, Chairman and CEO.
About Tianyin Pharmaceuticals
Tianyin is a manufacturer and supplier of modernized Traditional Chinese
Medicine ("TCM") in China. It was established in 1994 and acquired by the
current management team in August 2003. It has a comprehensive product
portfolio of 34 modernized TCMs in the market, 22 of which are listed in the
highly selective National Medicine Catalog of the National Medical Insurance
Program. Tianyin owns and operates two GMP manufacturing facilities and an R&D
platform supported by leading Chinese academic institutions. The Company has a
pipeline of 51 pharmaceutical products pending approval. Tianyin has an
extensive nationwide distribution network throughout China with a sales force
of 523 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with
two manufacturing facilities and a total of 1,187 employees. Tianyin achieved
revenue of $20.4 million and net income of $3.95 million in FY2007 ending June
30, 2007.
Safe Harbor Statement
The Statements which are not historical facts contained in this press
release are forward-looking statements that involve certain risks and
uncertainties including but not limited to risks associated with the
uncertainty of future financial results, additional financing requirements,
development of new products, government approval processes, the impact of
competitive products or pricing, technological changes, the effect of economic
conditions and other uncertainties detailed in the Company's filings with the
Securities and Exchange Commission.
For more information, please contact:

Company:
Allen Tang, Ph.D., MBA, Assistant to the CEO
Tel: +86-15821225642 (China)
Email: Allen.y.tang@gmail.com

Investors:
HC International, Inc.
Alan Sheinwald
Tel: +1-914-669-0222 (US)
Email: Alan.Sheinwald@hcinternational.net

SOURCE Tianyin Pharmaceutical, Co., Inc.

Company, Allen Tang, Ph.D., MBA, Assistant to the CEO, +86- 15821225642
(China), Allen.y.tang@gmail.com; Investors, Alan Sheinwald of HC
International, Inc., +1-914-669-0222 (US), or
Alan.Sheinwald@hcinternational.net, both for Tianyin Pharmaceutical, Co.,
Inc.